Tepezza (teprotumumab-trbw) / Roche, Amgen 
Welcome,         Profile    Billing    Logout  
 18 Diseases   3 Trials   3 Trials   723 News 


«123456789»
  • ||||||||||  Review, Journal:  Emerging therapies in the medical management of thyroid eye disease. (Pubmed Central) -  Jul 10, 2024   
    Tocilizumab, a monoclonal antibody of interleukin 6, has played a role in the management of multiple autoimmune and inflammatory conditions and may offer promise in TED...Among the agents under investigation that aim to decrease ocular morbidity associated with TED are agents that IGF-1R, interleukin 6, and the neonatal Fc receptor. The management of TED continues to expand with novel immunologic approaches for disease therapy.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  The association of race with thyroid eye disease presentation and outcomes. (Pubmed Central) -  Jul 10, 2024   
    Black patients presented with fewer external exam findings suggestive of active TED compared to White patients, but the rate of compressive optic neuropathy and decompression surgery were similar in the two groups. These differences may be due to disease phenotypes, which warrant further study.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Orbital corticosteroid injections for the treatment of active thyroid eye disease. (Pubmed Central) -  Jul 10, 2024   
    To study the efficacy of orbital injections of triamcinolone acetonide mixed 1:1 with dexamethasone in the treatment of active thyroid eye disease...No steroid-responsive increases in intraocular pressure or injection-related complications were reported. Orbital steroid injections can successfully reduce symptoms of TED and may be a reliable tool in the treatment of TED as a relatively safe, fast-acting, efficacious treatment option, particularly as a bridge to other therapies.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Teprotumumab for Thyroid Eye Disease-related Strabismus. (Pubmed Central) -  Jul 5, 2024   
    Extraocular motility in all 4 ductions also improved. A substantial minority of patients still required strabismus surgery following teprotumumab.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Review, Journal:  A Review of Novel Medical Treatments for Thyroid Eye Disease. (Pubmed Central) -  Jun 13, 2024   
    Recently, several clinical trials are underway to assess the efficacy and safety of novel drugs targeting mTORC1, IL-6, FcRN, and IGF-1R in treating TED. With the explosive increase in interest from academia and pharmaceutical companies in TED, there is anticipation for the development of drugs that are equivalent or superior to teprotumumab while being safer.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Reactivation after teprotumumab treatment for active thyroid eye disease. (Pubmed Central) -  Jun 9, 2024   
    The proptosis and CAS regression occurs in the setting of disease reactivation in 80% of regressions. Teprotumumab treatment appears to offer minimal long-term improvement in diplopia.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Clinical, Journal:  Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials. (Pubmed Central) -  Jun 2, 2024   
    Inflammatory and ophthalmic composite outcome improvements were seen in 90% of patients with nearly 70% reporting improvement in diplopia and proptosis. Further, 82% of patients in this analysis did not report additional TED treatment (including surgery) over 99 weeks following the final teprotumumab dose.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Immune checkpoints: new insights into the pathogenesis of thyroid eye disease. (Pubmed Central) -  May 31, 2024   
    This review will examine the overall pathogenic mechanism linked to the immune cells of TED and then discuss the latest research findings on the immunomodulatory role of ICs in the development and pathogenesis of TED. This will offer fresh perspectives on the study of pathogenesis and the identification of potential therapeutic targets.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Review, Journal:  The changing landscape of thyroid eye disease: current clinical advances and future outlook. (Pubmed Central) -  May 25, 2024   
    Long-term safety profiles will require clarification as unintended immunological consequence downstream may become manifest as seen in other diseases. Finally, future novel therapeutics will entail significant expenditure and may lead to a divergence of available treatment modalities between healthcare systems due to funding disparities.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Clinical, Journal, Adverse events:  Re: Shah et (Pubmed Central) -  May 22, 2024   
    Finally, future novel therapeutics will entail significant expenditure and may lead to a divergence of available treatment modalities between healthcare systems due to funding disparities. No abstract available
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal, Surgery:  Outcomes of Strabismus Surgery Following Teprotumumab Therapy. (Pubmed Central) -  May 16, 2024   
    This is the first retrospective study of patient-reported side effects and adverse events experienced by a cohort of teprotumumab users. Most patients requiring surgery for strabismic diplopia following teprotumumab achieve good outcomes with success rates comparable to series published before the availability of teprotumumab.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    New P1 trial:  A Study of TEPEZZA (clinicaltrials.gov) -  Apr 28, 2024   
    P1,  N=16, Completed, 
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Teprotumumab improves light sensitivity in patients with thyroid eye disease. (Pubmed Central) -  Apr 19, 2024   
    Teprotumumab improves light sensitivity in patients with acute and chronic TED. The results of this study highlight that the improvements in light sensitivity following treatment are not directly related to the mechanical changes in TED, suggesting another underlying mechanism is
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Teprotumumab in thyroid eye disease. (Pubmed Central) -  Apr 17, 2024   
    In this review, we summarize the clinical features and pathophysiology of TED, disease course, and traditional management methods. We further detail the development of teprotumumab, the founding studies that brought it to its FDA approval, adverse events profile, and ongoing as well as future investigations.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Evidence Gap Analysis of the Burden of Illness and Treatment of Thyroid Eye Disease () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2255;    
    TED negatively affects patient vision, health-related quality of life, and ability to work. Despite current treatment options, there is an unmet need for a new, effective treatment with a beneficial safety profile to control the symptoms of this potentially sight-threatening condition.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
    Evidence Gap Analysis of the Burden of Disease in Thyroid Eye Disease () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1754;    
    Despite current treatment options, there is an unmet need for a new, effective treatment with a beneficial safety profile to control the symptoms of this potentially sight-threatening condition. We identified several gaps in the literature including the lack of standardized diagnostic criteria for TED , the lack of robust long-term data on current TED therapie s, and the need f or additional clinical, humanistic, and economic burden studies in patients with TED.
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Journal:  Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease. (Pubmed Central) -  Feb 19, 2024   
    There are some baseline measures, such as CAS and right and left gaze horizontal prism deviation that can help better predict how a patient will respond to teprotumumab treatment. Our results can better inform physicians of how to counsel patients with TED when considering teprotumumab therapy.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Phase classification:  TEPEZZA (clinicaltrials.gov) -  Feb 15, 2024   
    P4,  N=313, Active, not recruiting, 
    Our results can better inform physicians of how to counsel patients with TED when considering teprotumumab therapy. Phase classification: P3b/4 --> P4
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Clinical:  Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report. (Pubmed Central) -  Dec 19, 2023   
    While teprotumumab has been shown to be efficacious, our patient with TSHRAb-positive euthyroid thyroid-associated ophthalmopathy who presented with diplopia did not have any significant improvement following the standard treatment dose of eight infusions over a 24-week period. This case underscores not only barriers to treatment, such as the high cost of teprotumumab but also highlights the importance of identifying risks for nonresponse.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Trial completion:  A Study Evaluating TEPEZZA (clinicaltrials.gov) -  Nov 7, 2023   
    P4,  N=62, Completed, 
    N/A. Active, not recruiting --> Completed
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Incidence of Hyperglycemia in Patients Treated With Teprotumumab (DEMAND) -  Oct 28, 2023 - Abstract #AAO2023AAO_2174;    
    Conclusion The incidence of TRH was higher in TED patients in comparison with oncology patients. With the recent approval of teprotumumab for TED, more patients with dysglycemia are taking teprotumumab in a real-world setting, and further studies are required to explain the disparate incidence of hyperglycemia.
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Teprotumumab-Associated Hearing-Related Adverse Events: A Narrative Review of the Literature (DEMAND) -  Oct 28, 2023 - Abstract #AAO2023AAO_2133;    
    Proposed treatment for hearing impairment includes local insulin-like growth factor injections and reducing teprotumumab dose. Conclusions There remains a need for both standardized screening guidelines and treatment for patients with persistent ototoxicity.
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Long-Term Follow-Up of Hearing Dysfunction After Treatment With Teprotumumab for TED (POSTER THEATER) -  Oct 28, 2023 - Abstract #AAO2023AAO_1817;    
    Conclusion Hearing dysfunction is one of the concerning adverse effects from teprotumumab. Baseline and periodical otolaryngology evaluation, audiometry and PET are necessary for every patient planning to receive infused teprotumumab.
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen
    Frequency and Patterns of Hearing Dysfunction in Patients Treated With Teprotumumab (WEST 2006) -  Oct 28, 2023 - Abstract #AAO2023AAO_1647;    
    Conclusion Audiometric data demonstrates that teprotumumab influences hearing function, most significantly at higher frequencies and in older patients. Audiometric testing is critical for counseling patients regarding teprotumumab treatment.
  • ||||||||||  Tepezza (teprotumumab) / Roche, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Review, Journal:  Roles of four targets in the pathogenesis of graves' orbitopathy. (Pubmed Central) -  Oct 9, 2023   
    However, as a second-line treatment for GO, targeted drugs such as tocilizumab and rituximab have very limited therapeutic effects and may be accompanied by side effects. The introduction of Teprotumumab, which targets IGF-IR, has made significant progress in the clinical management of GO...In this discussion, we explore the pathogenesis of GO and relevant work, and highlight four potential targets for GO: Interleukin-23 receptor (IL-23
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Roche
    Journal:  Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease. (Pubmed Central) -  Oct 4, 2023   
    The occurrence of regression was independent of the pretreatment duration of clinical thyroid eye disease. Overall, compared with preteprotumumab, there was a greater amount of improvement than regression at most recent follow-up.